Metronome LLC v. Irwin Naturals: Cannabis Patent Case Ends in Voluntary Dismissal in 59 Days

Case Overview

A cannabis-derived topical treatment patent infringement action filed in the Nevada District Court concluded swiftly — and quietly — when plaintiff Metronome LLC voluntarily dismissed its case against supplement manufacturer Irwin Naturals just 59 days after filing. The dismissal, entered without prejudice on February 9, 2026, leaves the door open for future litigation while raising pointed questions about litigation strategy, patent assertion timing, and the evolving landscape of cannabis-derived botanical drug product patent enforcement.

At the center of the dispute was U.S. Patent No. US10653736B2, covering topical treatments incorporating cannabis-derived botanical drug products — a commercially significant technology area as the legal cannabis and hemp-based wellness industries continue to expand aggressively into mainstream consumer markets. For patent attorneys, IP professionals, and R&D teams operating in the cannabis and nutraceutical sectors, this case offers instructive lessons about pre-answer voluntary dismissals, patent assertion strategy, and freedom-to-operate risk management.

Case No. 2:25-cv-02471 | Nevada District Court | Filed: December 12, 2025 | Closed: February 9, 2026

The Parties

The Patent at Issue

This case involved a key patent covering formulation technology at the intersection of cannabis-derived compounds and pharmaceutical-grade topical delivery — a space experiencing rapid commercial growth and increasing patent enforcement activity. The patent is registered with the U.S. Patent and Trademark Office (USPTO).

• • US10653736B2 — Topical treatments incorporating cannabis sp. derived botanical drug products
• • Application Number: US16/257389
• • Technology Area: Cannabis-derived topical treatments

The complaint targeted Irwin Naturals’ topical treatments incorporating cannabis-derived botanical drug products, a category that broadly aligns with the company’s hemp and CBD-infused topical product lines marketed to mainstream wellness consumers.

Legal Representation

Metronome LLC was represented by attorneys **Glenn Truitt** and **Isaac Rabicoff**, with legal services provided through **Private Wealth Law Inc.** and **Rabicoff Law LLC**. Isaac Rabicoff and Rabicoff Law LLC are recognized names in patent litigation, particularly in asserting patents across technology and consumer product sectors. No defense counsel entered an appearance before the case was dismissed.

Litigation Timeline & Procedural History

The action was filed in the United States District Court for the District of Nevada — a venue that, while less traditionally associated with high-volume patent dockets, represents a deliberate venue choice that practitioners should note when assessing plaintiff strategy.

The case resolved entirely at the pre-answer stage. Critically, **Irwin Naturals had not yet filed an answer to the complaint, nor had it moved for summary judgment** at the time of dismissal. No claim construction proceedings, Markman hearings, inter partes review petitions, or substantive motions appear in the record during this 59-day window. The compressed timeline — under two months from filing to closure — signals that this dispute resolved through early-stage dynamics rather than merits-based adjudication.

The Verdict & Legal Analysis

Outcome

Metronome LLC filed a notice of voluntary dismissal without prejudice pursuant to Federal Rule of Civil Procedure 41(a)(1)(A)(i) on February 9, 2026. Under this procedural rule, a plaintiff may dismiss an action without a court order if the defendant has not yet served an answer or a motion for summary judgment — precisely the circumstance present here. The dismissal carries no prejudice, meaning Metronome LLC retains the legal right to refile the same claims against Irwin Naturals in the future.

No damages were awarded. No injunctive relief was granted or denied on the merits. The court issued no substantive ruling on patent validity or infringement.

Verdict Cause Analysis

The case was initiated as a straightforward patent infringement action — the complaint alleged that Irwin Naturals’ topical cannabis products infringed claims of US10653736B2. However, the record contains no indication that substantive litigation proceeded beyond the filing stage.

Rule 41(a)(1)(A)(i) dismissals at the pre-answer stage are notable because they are **unilateral** — the plaintiff exercises a procedural right without requiring the defendant’s consent or the court’s permission. This mechanism is frequently employed in patent litigation for several strategic reasons:

• Settlement reached pre-litigation: Parties may have entered a licensing arrangement or reached a commercial resolution not reflected in the public docket.
• Plaintiff reassessment: The asserting party may have identified claim construction vulnerabilities, prior art issues, or infringement proof challenges upon closer post-filing review.
• Strategic repositioning: The plaintiff may be refiling in a different venue or amending the complaint to address deficiencies.
• Demand letter resolution: Cases originating from pre-suit licensing demand processes sometimes resolve quickly when the defendant engages commercially.

Because no defendant counsel entered an appearance and no responsive pleading was filed, the public record provides limited visibility into which of these dynamics drove the dismissal.

Legal Significance

From a doctrinal perspective, this case generated no precedential ruling. The voluntary pre-answer dismissal means there is no claim construction order, no validity determination, and no infringement finding on record. Patent US10653736B2 remains an active, enforceable patent that Metronome LLC could assert again.

For practitioners tracking cannabis patent enforcement, this outcome underscores that the absence of a merits ruling does not diminish the patent’s threat value. Pre-answer dismissals — particularly without prejudice — can reflect successful monetization rather than litigation failure.

Strategic Takeaways

For Patent Holders: A Rule 41(a)(1)(A)(i) dismissal preserves maximum future optionality. Plaintiffs who achieve licensing objectives early can exit cleanly while retaining enforcement rights against the same or different defendants.

For Accused Infringers: Early engagement — including rapid freedom-to-operate analysis and pre-answer settlement posture — can resolve disputes before costly litigation escalates. The absence of defendant counsel in this record suggests Irwin Naturals may have managed the matter through business-level resolution channels.

For R&D Teams: US10653736B2 remains a live patent covering cannabis-derived topical formulation technology. Companies developing or commercializing similar products should conduct freedom-to-operate (FTO) analysis with respect to this patent before product launch.

Industry & Competitive Implications

The cannabis-derived topical treatment market is experiencing accelerating patent enforcement activity as early-stage patent filings from the 2015–2020 period mature into issued patents. US10653736B2 represents precisely this wave — a granted patent covering formulation technology now commercially deployed across the hemp wellness industry.

For companies like Irwin Naturals and its competitors, the Metronome LLC action illustrates that no brand operating in the CBD or cannabis topical space is insulated from infringement assertions, regardless of market position or product mainstream acceptance. The wellness supplement industry — where Irwin Naturals competes — faces compounding exposure as patent holders with cannabis-derived formulation IP become more assertive.

The swift, pre-answer resolution also reflects a broader litigation trend: early-stage patent settlements and licensing resolutions that avoid docket exposure, reduce litigation cost, and preserve commercial relationships. Whether this case resolved through a licensing agreement or strategic withdrawal, the 59-day lifecycle aligns with pre-suit resolution patterns increasingly favored by both plaintiffs and defendants in non-complex patent assertion matters.